Nuvation Bio Inc. (NUVB) News
Track canonical SquawkNews coverage tagged to NUVB, Nuvation Bio Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 22 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
FDA approves Nuvation Bio IBTROZI sNDA, NUVB jumps 6%
The FDA approved Nuvation Bio’s supplemental New Drug Application for IBTROZI (taletrectinib), updating the label for the ROS1 inhibitor ahead of the PDUFA target date. NUVB shares rose more than 6% to $6.130.
REGULATION | Sep 17, 2026, 04:46 PM UTC
M
Nuvation Bio gets FDA approval for IBTROZI® label update
FDA approved Nuvation Bio’s supplemental new drug application for IBTROZI® (taletrectinib), updating TRUST-I data to reflect a nearly 50-month median duration of response in TKI-naïve advanced ROS1-positive non-small cel
REGULATION | Sep 17, 2026, 11:31 AM UTC
L
NUVB - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1- Positive Non-Small Cell Lung Cancer
NUVB - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1- Positive Non-Small Cell Lung Cancer
REGULATION | Sep 17, 2026, 11:31 AM UTC
L
NUVB - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
NUVB - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
NEWS | Sep 15, 2026, 12:04 PM UTC
L
Nuvation Bio Inc. (NYSE:NUVB) Reports Consistent IBTROZI Efficacy Across ROS1+ NSCLC Subgroups
Nuvation Bio announced new pooled TRUST-I/II analyses showing IBTROZI (taletrectinib) efficacy durable and consistent regardless of prior chemotherapy or ROS1 fusion partner in advanced ROS1+ NSCLC, with safety in line w
NEWS | Sep 15, 2026, 12:02 PM UTC
L
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroupsAmong pati
NEWS | Sep 15, 2026, 12:01 PM UTC
L
NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities
IBTROZI leads the ROS1 TKI market with strong efficacy and safety, while safusidenib shows unprecedented results in glioma, positioning it for significant market expansion. Educational efforts and improved testing are dr
EQUITY | Sep 09, 2026, 03:08 PM UTC
L
NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead
IBTROZI leads the ROS1 TKI market with strong efficacy and safety, while safusidenib shows unprecedented results in glioma and is poised for earlier regulatory milestones. The addressable markets for both drugs are subst
EQUITY | Sep 09, 2026, 02:17 PM UTC
H
Jim Cramer highlights NUVB Fast Track and favors CRWV, BOX
On CNBC’s “Mad Money Lightning Round,” Jim Cramer called Nuvation Bio a “pure spec” after its FDA Fast Track Designation. He favored CoreWeave over “neoclouds” and praised Box after its Q2 results.
EARNINGS | Sep 04, 2026, 11:07 AM UTC
L
NUVB - Nuvation Bio to Participate in Upcoming Investor Conferences
NUVB - Nuvation Bio to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:06 PM UTC
L
NUVB Initiated Overweight, a low-risk, high-reward commercial-stage Oncology story built on two best-in-class targeted Therapies @ Cantor
NUVB Initiated Overweight, a low-risk, high-reward commercial-stage Oncology story built on two best-in-class targeted Therapies @ Cantor
EQUITY | Aug 21, 2026, 12:07 PM UTC
L
NUVB initiated with Overweight by Cantor Fitzgerald
Hammerstone MarketTalk reports Cantor Fitzgerald initiated NUVB with an Overweight rating; the note provides no valuation metrics or stated catalyst in the feed.
EQUITY | Aug 21, 2026, 11:58 AM UTC
M
Nuvation Bio gets FDA Fast Track for safusidenib in glioma
Nuvation Bio says the FDA granted Fast Track designation for safusidenib in IDH1-mutant glioma, with pivotal Phase 3 Sigma study enrollment underway.
REGULATION | Aug 20, 2026, 12:53 PM UTC
M
Nuvation Bio gets FDA Fast Track for safusidenib in glioma
Nuvation Bio says the FDA granted Fast Track designation to safusidenib for treatment of IDH1-mutant glioma.
REGULATION | Aug 20, 2026, 12:01 PM UTC
L
NUVB - Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
NUVB - Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 06, 2026, 11:31 AM UTC
M
Nuvation Bio Presents New Subgroup Analyses
Nuvation Bio presents new subgroup analyses for IBTROZI
EQUITY | Aug 04, 2026, 12:03 PM UTC
L
NUVB Maintain Market Outperform, $10 PT after GSK FDA approval @ Citizens
NUVB Maintain Market Outperform, $10 PT after GSK FDA approval @ Citizens
REGULATION | Jul 23, 2026, 11:19 AM UTC
H
Nuvation Bio price target lowered to $19 from $20 at RBC Capital
RBC Capital lowered the firm's price target on Nuvation Bio to $19 from $20 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked
RATES | Jul 07, 2026, 11:31 AM UTC
M
NUVB Prices $250M Notes
Nuvation Bio announces pricing of upsized offering of $250.0 million of convertible senior notes
EQUITY | Jun 26, 2026, 09:09 AM UTC
H
SPRY -24% on Update
SPRY falls 24% premarket after providing commercial and financial updates, while other big cap stocks also decline on various news
EQUITY | Jun 25, 2026, 12:17 PM UTC
M
FUL, TCOM, HTZ Drop
H.B. Fuller, Trip.com, and Hertz Global are among the stocks moving lower in Thursday's pre-market session
EQUITY | Jun 25, 2026, 12:08 PM UTC
M
NUVB Offers Notes
Nuvation Bio announces proposed convertible senior notes offering
EQUITY | Jun 25, 2026, 11:01 AM UTC